Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) H 1 NMR spectra of Chitosan-CPBA and (B) Chitosan. (C) Hydrodynamic size and (D) zeta potential of liposome (LP) and liposome-chitosan (LPC) NPs. (E) Hydrodynamic size and (F) zeta potential of liposome (LP) and liposome-chitosan-CPBA (LPCB) NPs. (G) Cumulative doxorubicin (Dox) release from Dox and R848 coloaded liposome-chitosan-CPBA (LPCBDR) and liposome-chitosan (LPCDR) NPs at different pH conditions (6.4, 7.4). (H) Cumulative R848 release from LPCBDR and LPCDR NPs at different pH conditions (6.4, 7.4). Data was presented as mean ± SEM ( n = 3 replicates).

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Zeta Potential Analyzer

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) Treatment schedule for different groups of C57BL/6 mice bearing subcutaneous MB49 tumors, with intravenous administration of doxorubicin (20 μ g/mouse) and R848 (8 μ g/mouse), given three times in total. (B) Tumor growth curves of MB49 subcutaneous tumors in C57BL/6 mice across different treatment groups during treatment ( n = 5). (C) Body weight changes of mice during treatment. (D) Representative images of tumors harvested from each group on Day 21. (E) Tumor volumes and (F) tumor weights of tumors collected on Day 21. Treatment groups: PBS group, mice received 100 μ L of PBS; free Dox and R848 group (FDR), mice received a combination of 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-Dox-R848 group (LPCDR), mice received LPCDR NPs containing 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-CPBA-Dox-R848 group (LPCBDR), mice received LCBDR NPs containing the same dose of Dox and R848 in 100 μ L of PBS. * P < 0.05; ** P < 0.01; *** P < 0.001. Data was presented as mean ± SEM.

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques:

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: a And then LPCBDR NPs were intravenously injected into MB49 subcutaneous tumor-bearing mice. LPCBDR NPs could actively target the tumor site and release Dox and R848. This targeted drug delivery method facilitated tumor cell eradication, thereby achieving a therapeutic effect.

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Injection

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) H 1 NMR spectra of Chitosan-CPBA and (B) Chitosan. (C) Hydrodynamic size and (D) zeta potential of liposome (LP) and liposome-chitosan (LPC) NPs. (E) Hydrodynamic size and (F) zeta potential of liposome (LP) and liposome-chitosan-CPBA (LPCB) NPs. (G) Cumulative doxorubicin (Dox) release from Dox and R848 coloaded liposome-chitosan-CPBA (LPCBDR) and liposome-chitosan (LPCDR) NPs at different pH conditions (6.4, 7.4). (H) Cumulative R848 release from LPCBDR and LPCDR NPs at different pH conditions (6.4, 7.4). Data was presented as mean ± SEM ( n = 3 replicates).

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Zeta Potential Analyzer

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: Mean fluorescence intensity (MFI) quantification of sialic acid expression levels on the surface of (A) T24 cells and (C) MB49 cells after incubation with different concentrations of TNF- α (0, 20, and 100 ng mL −1 ) for 48 h. MFI quantification of (B) T24 cells and (D) MB49 cells pretreated with TNF- α for 48 h, followed by a 1-h coincubation with coumarin-6 loaded LPCB and LPC NPs at 37 °C at different pH (6.4, 7.4). Cytotoxicity of (E) T24 cells and (F) MB49 cells after treatment with different concentrations of Dox (0.25, 1, and 2.5 μ g mL −1 ) of free Dox (FD), Dox and R848 coloaded liposome-chitosan (LPCDR) NPs, and Dox and R848 coloaded liposome-chitosan-CPBA (LPCBDR) NPs after 20 ng mL −1 TNF- α pretreatment for 48 h.* P < 0.05; ** P < 0.01;*** P < 0.001. Data was presented as mean ± SEM ( n = 4 replicates).

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Fluorescence, Expressing, Incubation

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: Total percentage of (A) CD40 + BMDCs, (B) CD80 + BMDCs, and (C) CD86 + BMDCs after 48-h incubation with 10 μ M OVA257–264 peptide admixed with 10 ng mL −1 of free R848 (FR), R848-loaded liposome-chitosan (LPCR) NPs, or R848-loaded liposome-chitosan-CPBA (LPCBR) NPs. (D) IL-12p70 cytokine secretion levels from BMDCs after 48-h treatment under the same conditions. * P < 0.05; ** P < 0.01; *** P < 0.001. Data was presented as mean ± SEM ( n = 4 replicates).

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Incubation

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) Treatment schedule for different groups of C57BL/6 mice bearing subcutaneous MB49 tumors, with intravenous administration of doxorubicin (20 μ g/mouse) and R848 (8 μ g/mouse), given three times in total. (B) Tumor growth curves of MB49 subcutaneous tumors in C57BL/6 mice across different treatment groups during treatment ( n = 5). (C) Body weight changes of mice during treatment. (D) Representative images of tumors harvested from each group on Day 21. (E) Tumor volumes and (F) tumor weights of tumors collected on Day 21. Treatment groups: PBS group, mice received 100 μ L of PBS; free Dox and R848 group (FDR), mice received a combination of 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-Dox-R848 group (LPCDR), mice received LPCDR NPs containing 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-CPBA-Dox-R848 group (LPCBDR), mice received LCBDR NPs containing the same dose of Dox and R848 in 100 μ L of PBS. * P < 0.05; ** P < 0.01; *** P < 0.001. Data was presented as mean ± SEM.

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques:

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) Schematic illustration of tumor tissue collection and flow cytometric analysis on Day 21 post-treatment. Tumors were harvested, enzymatically digested, stained, and analyzed by flow cytometry on Day 21. Proportion of (B) CD44 + CD4 T cells, CD107a + CD4 T cells, Granzyme B (GrzB) + CD4T cells, IFN- γ + CD4T cells, (C) IFN- γ + NK cells, GrzB + NK cells, (D) CD44 + CD8a T cells, and GrzB + CD8a T cells in tumor tissues from different treatment groups ( n = 5). Treatment groups: PBS group, mice received 100 μ L of PBS; free Dox and R848 group (FDR), mice received a combination of 20 μ g Dox and 8 μ g R848 in 100 μ L of PBS; liposome-chitosan-Dox-R848 group (LPCDR), mice received LPCDR NPs containing 20 μ g Dox and 8 μ g R848 in 100 μ L of PBS; liposome-chitosan-CPBA-Dox-R848 group (LPCBDR), mice received LCBDR NPs containing the same dose of Dox and R848 in 100 μ L of PBS. * P < 0.05; ** P < 0.01; *** P < 0.001. Data was presented as mean ± SEM.

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Staining, Flow Cytometry